奥希替尼治疗EGFR基因敏感突变晚期肺腺癌的疗效及脑转移的影响因素分析-现代医学

奥希替尼治疗EGFR基因敏感突变晚期肺腺癌的疗效及脑转移的影响因素分析

单位：1. 邢台市第三医院药剂科, 河北邢台 054000;
2. 邢台医学高等专科学校第二附属医院临床药学科, 河北邢台 054000

分类号：R734.2

出版年·卷·期（页码）：2021·49·第三期（273-279）

摘要：

目的：探讨奥希替尼治疗EGFR基因敏感突变晚期肺腺癌的疗效及其预防脑转移的作用机制。方法：回顾性选取邢台市第三医院于2017年1月至2019年1月收治的68例EGFR基因敏感突变晚期肺腺癌患者为研究对象，根据治疗方法将患者分成两组，分别为奥希替尼组（42例）和吉非替尼组（26例）。比较两组患者临床疗效、脑转移率，肿瘤标志物[细胞角蛋白19片段（CYFRA21-1）、糖类抗原125（CA125）、血管内皮生长因子（VEGF）]水平以及四跨膜蛋白CD151表达水平、不良反应以及生存情况。另根据患者治疗期间是否发生脑转移分为脑转移组和未脑转移组，比较两组患者CD151表达水平，并采用Cox模型进行生存预后多因素分析。结果：奥希替尼组客观有效率（ORR）、疾病控制率（DCR）明显高于吉非替尼组（P<0.05）。治疗后，奥希替尼组患者肿瘤标志物和CD151水平显著低于吉非替尼组（P<0.05）。奥希替尼组患者中位生存时间[（11.06±0.32）月]长于吉非替尼组患者中位生存时间[（9.09±0.21）月]（log-rank P=0.024）。TNM分期、发生脑转移、吸烟是影响EGFR基因敏感突变晚期肺腺癌患者预后的独立危险因素。奥希替尼组新发脑转移率（21.62%）显著低于吉非替尼组（45.83%）（P<0.05），脑转移组CD151表达水平显著高于未脑转移组（P<0.05）。结论：奥希替尼治疗EGFR基因敏感突变晚期肺腺癌临床疗效显著，其作用机制可能是通过CD151调控相关通路蛋白表达，从而影响肺癌细胞增殖和迁移过程，延长患者生存期。

Objective: To investigate the efficacy of osimertinib in the treatment ofadvanced lung adenocarcinoma with sensitive mutation of EGFR gene and analysis of the factors affectingbrain metastasis. Methods: Retrospectively selected 68 cases of advanced lung adenocarcinoma patients with sensitive mutation ofEGFR gene who were admitted to the Third Hospital of Xingtai City from January 2017 to January 2019 as the research objects. According to different treatment method, they were divided into the osimertinib group(42 cases) and the gefitinib group(26 cases). The clinical efficacy, brain metastasis rate, the levels of tumor markers[cytokeratin 19 fragment (CYFRA21-1), carbohydrate antigen 125 (CA125), vascular endothelial growth factor (VEGF)]and four transmembrane protein CD151 were compared between the two groups. In addition, patients were divided into brain metastasis group and non-brain metastasis group according to whether the patients had brain metastasis during treatment. The CD151 expression levels of the two groups were compared, and the Cox model was used for multi-factor analysis of survival and prognosis. Results: The objective response rateand disease control rate in the osimertinib group were significantly higher than those in the gefitinib group (P<0.05). After treatment, the levels of tumor markers and CD151 in the osimertinib group were significantly lower than those in the gefitinib group (P<0.05). The median survival time of patients in the osimertinib group[(11.06±0.32) months] was longer than that of gefitinib[(9.09±0.21) months] (log-rank P=0.024). TNM stage, brain metastasis, and smoking were independent risk factors which affected the prognosis of advanced lung adenocarcinomapatients with sensitive mutation of EGFR gene. The rate of new brain metastasis (21.62%) in the oxitinib group was significantly lower than that in the gefitinib group (45.83%) (P<0.05), and the expression level of CD151 in the brain metastasis group was significantly higher than that in the non-brain metastasis group (P<0.05). Conclusion: Osimertinib has significant clinical efficacy in the treatment ofadvanced lung adenocarcinoma with EGFR gene-sensitive mutations. The mechanism of action may be throughCD151 regulatingthe expression of related pathwwayproteins, thereby affecting the proliferation and migration of lung cancer cells and prolonging the survival of patients. period.

参考文献：

[1] ZHANG Z H,SHI L L,WU C W,et al.Construction of a supramolecular drug-drug delivery system for non-small-cell lung cancer therapy[J].ACS Appl Mater Interfaces,2017,9(35):29505-29514.
[2] YAO Z H,LIAO W Y,HO C C,et al.Incidence of hepatitis B reactivation during epidermal growth factor receptor tyrosine kinase inhibitor treatment in non-small-cell lung cancer patients[J].Eur J Cancer,2019,117(25):107-115.
[3] 张美玲,李春,叶茂松,等.改良Blocker PCR检测EGFR-TKI耐药后非小细胞肺癌血浆EGFR T790M突变的价值[J].复旦学报(医学版),2018,45(1):45-51.
[4] 卢尚辉,张小利,许信杰,等.奥希替尼在非小细胞肺癌中的耐药机制及治疗策略[J].肿瘤,2019,39(12):1031-1036.
[5] 查人俊.现代肺癌诊断与治疗[M].北京:人民军医出版社,1993:124-129.
[6] EDELINE J,BOUCHER E,ROLLAND Y,et al.Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma[J].Cancer,2012,118(1):254-259.
[7] 杨锁萍,丁为民,李凯,等.EGFR突变阴性非小细胞肺癌二、三线治疗的荟萃分析[J].东南大学学报(医学版),2015,34(6):859-867.
[8] 曹紫阳,吴伟,侯立坤,等.微滴数字PCR与Super-ARMS PCR检测非小细胞肺癌患者表皮生长因子受体(EGFR)酪氨酸激酶抑制剂治疗耐药后血浆游离DNA EGFR基因T790M突变的对比分析[J].中华病理学杂志,2018,47(12):910-914.
[9] 中国非小细胞肺癌患者EGFR T790M基因突变检测专家共识[J].中华医学杂志,2018,98(32):2544-2551.
[10] 陈君,黄佳丽,程志祥.奥希替尼对晚期非小细胞肺癌的治疗进展[J].东南大学学报(医学版),2020,39(1):90-94.
[11] 邵岚,张沂平.奥希替尼治疗晚期非小细胞肺癌的疗效及影响因素[J].中国新药与临床杂志,2020,39(3):155-161.
[12] MA R,FANG S K,HOU S,et al.Suspected brain metastasis from lung cancer mimicking intracerebral hemorrhage:a case report[J].Medicine,2018,97(10):e0106.
[13] 陈丽敏,傅梦姣,周建娅,等.EGFR-TKIs联合伽玛刀治疗EGFR突变的肺腺癌伴脑转移的预后分析[J].中国肺癌杂志,2019,22(5):64-70.
[14] GAVARA M M,ZAVERI K,BADANA A K,et al.A novel small molecule inhibitor of CD151 inhibits proliferation of metastatic triple negative breast cancer cell lines[J].Process Biochemistry,2018,66(1):254-262.
[15] 杨杰,袁晓晗,李凯.CD151及MMP-7在肺腺癌组织中的表达及其临床意义[J].肿瘤,2017,37(6):624-632.
[16] 王帅,张诗珩,张志敏,等.CD151通过上皮间质转化及干性相关通路调控非小细胞肺癌脑转移的机制研究[J].第三军医大学学报,2018,40(10):862-867.

服务与反馈：

【文章下载】【发表评论】【查看评论】【加入收藏】

提示：您还未登录，请登录！点此登录